Clinical evidence for the microbiome in inflammatory diseases

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Slingerland, Ann E ^a   Schwabkey, Zaker ^b   Wiesnoski, Diana H ^b   Jenq, Robert R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autoimmune diseases; Bacteria; Inflammation; Microbiome; Microbiota

Indexed keywords

PROBIOTIC AGENT; SYNBIOTIC AGENT;

ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; CROHN DISEASE; EVIDENCE BASED MEDICINE; FECAL MICROBIOTA TRANSPLANTATION; FIBROMYALGIA; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HUMAN; ILEITIS; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MICROBIOME; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS; VASCULITIS;

EID: 85018401859     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00400     Document Type: Review

References (175)

1. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A (2010) 107:11971-5. doi:10.1073/pnas.1002601107
2. Avershina E, Storro O, Oien T, Johnsen R, Pope P, Rudi K. Major faecal microbiota shifts in composition and diversity with age in a geographically restricted cohort of mothers and their children. FEMS Microbiol Ecol (2014) 87:280-90. doi:10.1111/1574-6941.12223
3. Gronlund MM, Grzeskowiak L, Isolauri E, Salminen S. Influence of mother's intestinal microbiota on gut colonization in the infant. Gut Microbes (2011) 2:227-33. doi:10.4161/gmic.2.4.16799
4. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med (2014) 6:237ra65. doi:10.1126/scitranslmed.3008599
5. Baskaradoss JK, Geevarghese A, Kutty VR. Maternal periodontal status and preterm delivery: a hospital based case-control study. J Periodontal Res (2011) 46:542-9. doi:10.1111/j.1600-0765.2011.01371.x
6. Human Microbiome Project Consortium. A framework for human microbiome research. Nature (2012) 486:215-21. doi:10.1038/nature11209
7. Rijkers GT, Bengmark S, Enck P, Haller D, Herz U, Kalliomaki M, et al. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr (2010) 140:671S-6S. doi:10.3945/jn.109.113779
8. Roberfroid M. Prebiotics: the concept revisited. J Nutr (2007) 137:830S-7S
9. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr (2001) 73:361s-4s
10. Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted therapies: an ecological perspective. Sci Transl Med (2012) 4:137rv5. doi:10.1126/scitranslmed.3004183
11. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol (2013) 29:79-84. doi:10.1097/MOG.0b013e32835a4b3e
12. Klemashevich C, Wu C, Howsmon D, Alaniz RC, Lee K, Jayaraman A. Rational identification of diet-derived postbiotics for improving intestinal microbiota function. Curr Opin Biotechnol (2014) 26:85-90. doi:10.1016/j.copbio.2013.10.006
13. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 3:390-407. doi:10.1038/ncpgasthep0528
14. Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis (2006) 12:925-33. doi:10.1097/01.mib.0000228998.29466.ac
15. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J (2008) 237:716-27. doi:10.1038/ismej.2008.37
16. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 105:16731-6. doi:10.1073/pnas.0804812105
17. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (1997) 11:853-8. doi:10.1046/j.1365-2036.1997.00225.x
18. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-23. doi:10.1136/gut.2003.037747
19. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 354:635-9. doi:10.1016/S0140-6736(98)06343-0
20. Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis (2014) 8:1498-505. doi:10.1016/j.crohns.2014.06.001
21. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med (2010) 10:13. doi:10.1186/1472-6882-10-13
22. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther (2012) 35:327-34. doi:10.1111/j.1365-2036.2011.04939.x
23. D'Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, et al. Rectal administration of Lactobacillus casei DG modifies flora composition and toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci (2011) 56:1178-87. doi:10.1007/s10620-010-1384-1
24. Soo I, Madsen KL, Tejpar Q, Sydora BC, Sherbaniuk R, Cinque B, et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol (2008) 22:237-42. doi:10.1155/2008/520383
25. Wu J, Nilsson A, Jönsson BAG, Stenstad H, Agace W, Cheng Y, et al. Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity. Biochem J (2006) 394:299-308. doi:10.1042/BJ20051121
26. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol (2009) 104:437-43. doi:10.1038/ajg.2008.118
27. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit (2004) 10:I126-31
28. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2009) 7:1209.e1. doi:10.1016/j.cgh.2009.07.016
29. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 105:2218-27. doi:10.1038/ajg.2010.218
30. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis (2010) 16:1286-98. doi:10.1002/ibd.21222
31. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther (2004) 20:1133-41. doi:10.1111/j.1365-2036.2004.02268.x
32. Cui H-H, Chen C-L, Wang J-D, Yang Y-J, Cun Y, Wu J-B, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol (2004) 10:1521-5. doi:10.3748/wjg.v10.i10.1521
33. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol (2010) 16:4145-51. doi:10.3748/wjg.v16.i33.4145
34. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis (2011) 5:115-21. doi:10.1016/j.crohns.2010.11.004
35. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc (2007) 66:307-15. doi:10.1017/S0029665107005563
36. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 119:305-9. doi:10.1053/gast.2000.9370
37. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 53:108-14. doi:10.1136/gut.53.1.108
38. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202-9. doi:10.1016/S0016-5085(03)00171-9
39. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis (2008) 14:662-8. doi:10.1002/ibd.20369
40. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther (2005) 22:721-8. doi:10.1111/j.1365-2036.2005.02642.x
41. Tomasz B, Zoran S, Jaroslaw W, Ryszard M, Marcin G, Robert B, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. Biomed Res Int (2014) 2014:208064-208064. doi:10.1155/2014/208064
42. Laake KO, Bjørneklett A, Bakka A, Midtvedt T, Norin KE, Eide TJ, et al. Influence of fermented milk on clinical state, fecal bacterial counts and biochemical characteristics in patients with ileal-pouch-anal-anastomosis. Microb Ecol Health Dis (1999) 11:211-7. doi:10.1080/08910609908540830
43. Brown SJ, Megan J, Smith S, Matchet D, Elliott R. Bifidobacterium longum BB-536 and prevention of acute pouchitis. Gastroenterology (2004) 126:A465-465
44. Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surg Today (2016) 46:939-49. doi:10.1007/s00595-015-1261-9
45. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther (2003) 17:509-15. doi:10.1046/j.1365-2036.2003.01465.x
46. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. Z Gastroenterol (1993) 31:129-34
47. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci (2000) 45:1462-4. doi:10.1023/A:1005588911207
48. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol (2008) 43:842-8. doi:10.1080/00365520801943354
49. Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol (2013) 11:982-7. doi:10.1016/j.cgh.2013.02.021
50. Madsen K, Backer JL, Leddin D, Dieleman LA, Bitton A, Feagan B, et al. M1207 A randomized controlled trial of VSL# 3 for the prevention of endoscopic recurrence following surgery for Crohn's disease. Gastroenterology (2008) 134:A-361. doi:10.1016/S0016-5085(08)61682-0
51. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut (2002) 51:405-9. doi:10.1136/gut.51.3.405
52. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol (2004) 4:5. doi:10.1186/1471-230X-4-5
53. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis (2005) 11:833-9. doi:10.1097/01.MIB.0000175905.00212.2c
54. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol (2015) 13:928.e-35.e. doi:10.1016/j.cgh.2014.10.031
55. Willert RP, Peddi KK, Ombiga J, Bampton PA, Lawrance IC. T1235 randomised, double-blinded, placebo-controlled study of VSL#3 versus placebo in the maintenance of remission in Crohns disease. Gastroenterology (2010) 138:S-517-S-518. doi:10.1016/S0016-5085(10)62390-6
56. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol (1997) 25:653-8. doi:10.1097/00004836-199712000-00021
57. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut (2006) 55:842-7. doi:10.1136/gut.2005.076604
58. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis (2007) 13:135-42. doi:10.1002/ibd.20063
59. Chiba M, Tsuji T, Nakane K, Komatsu M. High amount of dietary fiber not harmful but favorable for Crohn disease. Perm J (2015) 19:58-61. doi:10.7812/TPP/14-124
60. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med (2004) 13:643-7
61. Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol (2007) 7:36. doi:10.1186/1471-230X-7-36
62. Lindsay J, Whelan K, Stagg A, Gobin P, Al-Hassi H, Rayment N, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut (2006) 55:348-55. doi:10.1136/gut.2005.074971
63. Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut (2011) 60:923-9. doi:10.1136/gut.2010.232025
64. Casellas F, Borruel N, TorrejóN A, Varela E, Antolin M, Guarner F, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther (2007) 25:1061-7. doi:10.1111/j.1365-2036.2007.03288.x
65. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum (2002) 45:621-7. doi:10.1007/s10350-004-6257-2
66. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol (1991) 26:747-50. doi:10.3109/00365529108998594
67. Fernández-Bañares F, Hinojosa J, Sánchez-Lombrañ JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis for the Spanish group for the study of Crohn's disease and ulcerative colitis (GETECCU). Am J Gastroenterol (1999) 94(2):427-33. doi:10.1111/j.1572-0241.1999.872_a.x
68. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al. Synbiotic therapy (Bifidobacterium longum/synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut (2005) 54:242-9. doi:10.1136/gut.2004.044834
69. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, et al. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion (2011) 84:128-33. doi:10.1159/000322977
70. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, et al. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci (2007) 52:385-9. doi:10.1007/s10620-006-9549-7
71. Suskind D, Wahbeh G, Vendetoulli H, Singh N, Crohn's SM. Tu1754 fecal microbial transplant in pediatric Crohn's disease. Gastroenterology (2014) 146:S-834. doi:10.1016/S0016-5085(14)63030-4
72. Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis (2015) 21:556. doi:10.1097/MIB.0000000000000307
73. Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 30:51-8. doi:10.1111/jgh.12727
74. Vermeire S, Joossens M, Verbeke K, Hildebrand F, Machiels K, Van den Broeck K, et al. Sa1922 pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology (2012) 142:S-360. doi:10.1016/S0016-5085(12)61356-0
75. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 108:1620-30. doi:10.1038/ajg.2013.257
76. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 56:597-601. doi:10.1097/MPG.0b013e318292fa0d
77. Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, et al. Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. Gastroenterol Res Pract (2015) 2015:517597. doi:10.1155/2015/517597
78. Kao D, Madsen K. Fecal microbiota transplantation (FMT) in the treatment of inflammatory bowel disease (IBD): a case report. Am J Gastroenterol (2013) 108:S415-6. doi:10.1038/ajg.2013.267
79. Ren R, Sun G, Yang Y, Peng L, Zhang X, Wang S, et al. [A pilot study of treating ulcerative colitis with fecal microbiota transplantation]. Zhonghua Nei Ke Za Zhi (2015) 54:411-5
80. Scaldaferri F, Pecere S, Bruno G, Ianiro G, Laterza L, Gerardi V, et al. An open-label, pilot study to assess feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis: preliminary results. Gastroenterology (2015) 148:S870. doi:10.1016/S0016-5085(15)32950-4
81. Kump PK, Gröchenig H-P, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis (2013) 19:2155-65. doi:10.1097/MIB.0b013e31829ea325
82. Damman C, Brittnacher M, Hayden H, Radey M, Hager K, Miller S, et al. Su1403 single colonoscopically administered fecal microbiota transplant for ulcerative colitis-a pilot study to determine therapeutic benefit and graft stability. Gastroenterology (2014) 146:S-460. doi:10.1016/S0016-5085(14)61646-2
83. Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS One (2015) 10:e0133925. doi:10.1371/journal.pone.0133925
84. Borody T, Wettstein A, Campbell J, Leis S, Torres M, Finlayson S, et al. Fecal microbiota transplantation in ulcerative colitis: review of 24 years experience. Am J Gastroenterol (2012) 107:S665. doi:10.1038/ajg.2012.275
85. Borody T, Campbell J, Torres M, Nowak A, Leis S. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. Am J Gastroenterol (2011) 106:S352. doi:10.1038/ajg.2011.336_7
86. Vaughn BP, Gevers D, Ting A, Korzenik JR, Robson SC, Moss AC. Mo1228 fecal microbiota transplantation induces early improvement in symptoms in patients with active Crohn's disease. Gastroenterology (2014) 146:S-591-S-592. doi:10.1016/S0016-5085(14)62143-0
87. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease. Inflamm Bowel Dis (2016) 22:2182-90. doi:10.1097/MIB.0000000000000893
88. Kellermayer R, Nagy-Szakal D, Harris RA, Luna RA, Pitashny M, Schady D, et al. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol (2015) 110:604-6. doi:10.1038/ajg.2015.19
89. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology (2015) 149:102-9. doi:10.1053/j.gastro.2015.04.001
90. Rossen NG, Fuentes S, Van Der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology (2015) 149:110-8. doi:10.1053/j.gastro.2015.03.045
91. Choi J, Chung SW, Kim SJ, Kim SJ. Establishment of Porphyromonas gingivalis-specific T-cell lines from atherosclerosis patients. Oral Microbiol Immunol (2001) 16:316-8. doi:10.1034/j.1399-302x.2001.016005316.x
92. Mosorin M, Surcel HM, Laurila A, Lehtinen M, Karttunen R, Juvonen J, et al. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol (2000) 20:1061-7. doi:10.1161/01.ATV.20.4.1061
93. Marques da Silva R, Lingaas PS, Geiran O, Tronstad L, Olsen I. Multiple bacteria in aortic aneurysms. J Vasc Surg (2003) 38:1384-9. doi:10.1016/S0741-5214(03)00926-1
94. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev (2015) 14:269-76. doi:10.1016/j.autrev.2014.11.009
95. Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) (2011) 63:427-35. doi:10.1002/acr.20381
96. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J (1992) 82:158-61
97. Kalayoglu MV, Perkins BN, Byrne GI. Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect (2001) 3:963-9. doi:10.1016/S1286-4579(01)01458-7
98. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 19:576-85. doi:10.1038/nm.3145
99. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell (2016) 165:111-24. doi:10.1016/j.cell.2016.02.011
100. Bhatt AS, Manzo VE, Pedamallu CS, Duke F, Cai D, Bienfang DC, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol (2014) 66:1939-44. doi:10.1002/art.38631
101. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science (2009) 324:1190-2. doi:10.1126/science.1171700
102. Bieber T. Atopic dermatitis. N Engl J Med (2008) 358:1483-94. doi:10.1056/NEJMra074081
103. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res (2012) 22:850-9. doi:10.1101/gr.131029.111
104. Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Munoz-Planillo R, Hasegawa M, et al. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature (2013) 503:397-401. doi:10.1038/nature12655
105. Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune disease? Exp Dermatol (2015) 24:241-4. doi:10.1111/exd.12572
106. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One (2008) 3:e2719. doi:10.1371/journal.pone.0002719
107. Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res (2012) 304:15-22. doi:10.1007/s00403-011-1189-x
108. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, et al. Antibiotic exposure, infection, and the development of pediatric psoriasis: a nested case-control study. JAMA Dermatol (2016) 152:191-9. doi:10.1001/jamadermatol.2015.3650
109. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol (2011) 6:509-37. doi:10.1146/annurev-pathol-011110-130312
110. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, et al. The role of infections in the immunopathogensis of systemic sclerosis-evidence from serological studies. Ann N Y Acad Sci (2009) 1173:627-32. doi:10.1111/j.1749-6632.2009.04808.x
111. Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev (2011) 10:244-7. doi:10.1016/j.autrev.2010.09.010
112. Arron ST, Dimon MT, Li Z, Johnson ME, Wood TA, Feeney L, et al. High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis. J Invest Dermatol (2014) 134:2138-45. doi:10.1038/jid.2014.127
113. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med (2015) 21:895-905. doi:10.1038/nm.3914
114. Liu X, Zou Q, Zeng B, Fang Y, Wei H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. Curr Microbiol (2013) 67:170-6. doi:10.1007/s00284-013-0338-1
115. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition (2014) 30:430-5. doi:10.1016/j.nut.2013.09.007
116. Reichert S, Haffner M, Keysser G, Schafer C, Stein JM, Schaller HG, et al. Detection of oral bacterial DNA in synovial fluid. J Clin Periodontol (2013) 40:591-8. doi:10.1111/jcpe.12102
117. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum (2012) 64:3083-94. doi:10.1002/art.34539
118. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (2013) 2:e01202. doi:10.7554/eLife.01202
119. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med (2001) 344:350-62. doi:10.1056/NEJM200102013440507
120. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One (2010) 5:e8578. doi:10.1371/journal.pone.0008578
121. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med (2007) 357:1487-95. doi:10.1056/NEJMoa052632
122. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-associated differences in microbial composition of induced sputum. J Allergy Clin Immunol (2013) 131:e1-3. doi:10.1016/j.jaci.2012.11.013
123. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med (2013) 188:1193-201. doi:10.1164/rccm.201304-0775OC
124. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol (2011) 128:.e1-5. doi:10.1016/j.jaci.2011.04.060
125. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy (2014) 44:842-50. doi:10.1111/cea.12253
126. Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med (2015) 7:307ra152. doi:10.1126/scitranslmed.aab2271
127. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol (2009) 6:306-14. doi:10.1038/nrgastro.2009.35
128. Hohlfeld R. Multiple sclerosis: human model for EAE? Eur J Immunol (2009) 39:2036-9. doi:10.1002/eji.200939545
129. Dimachkie MM, Barohn RJ. Guillain-barré syndrome and variants. Neurologic Clinics (2013) 31(2):491-510. doi:10.1016/j.ncl.2013.01.005
130. Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev Neurother (2013) 13:11-9. doi:10.1586/14737175.2013.865867
131. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature (2011) 479:538-41. doi:10.1038/nature10554
132. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS One (2015) 10:e0137429. doi:10.1371/journal.pone.0137429
133. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MMP, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep (2016) 6:28484-28484. doi:10.1038/srep28484
134. Buscarinu MC, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi M, et al. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: a pilot study. Mult Scler (2016) 23(3):442-6. doi:10.1177/1352458516652498
135. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, et al. Gut microbiota in multiple sclerosis. J Invest Med (2015) 63:729-34. doi:10.1097/JIM.0000000000000192
136. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun (2016) 7:12015. doi:10.1038/ncomms12015
137. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, et al. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol (2016) 16:182. doi:10.1186/s12883-016-0703-3
138. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, et al. Gut microbiota composition and relapse risk in pediatric MS: a pilot study. J Neurol Sci (2016) 363:153-7. doi:10.1016/j.jns.2016.02.042
139. Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One (2013) 8:e76359. doi:10.1371/journal.pone.0076359
140. Borody T, Leis S, Campbell J, Torres M, Nowak A. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol (2011) 106:S352. doi:10.1038/ajg.2011.336_7
141. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol (2007) 61:97-108. doi:10.1002/ana.21067
142. Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler (2011) 17:743-54. doi:10.1177/1352458511398054
143. Lee SC, Tang MS, Lim YAL, Choy SH, Kurtz ZD, Cox LM, et al. Helminth colonization is associated with increased diversity of the gut microbiota. PLoS Negl Trop Dis (2014) 8:e2880. doi:10.1371/journal.pntd.0002880
144. Kaldor J, Speed BR. Guillain-Barre syndrome and Campylobacter jejuni: a serological study. Br Med J (1984) 288:1867-70. doi:10.1136/bmj.288.6434.1867
145. Winer JB, Hughes RAC, Anderson MJ, Jones DM, Kangro H, Watkinsii F. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry (1988) 51:613-8. doi:10.1136/jnnp.51.5.613
146. Mishu B. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barre syndrome. Ann Intern Med (1993) 118:947-947. doi:10.7326/0003-4819-118-12-199306150-00006
147. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med (1995) 333:1374-9. doi:10.1056/NEJM199511233332102
148. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann Neurol (2004) 33:243-7. doi:10.1002/ana.410330304
149. Pham TAN, Lawley TD. Emerging insights on intestinal dysbiosis during bacterial infections. Curr Opin Microbiol (2014) 17:67-74. doi:10.1016/j.mib.2013.12.002
150. Goldenberg DL. Fibromyalgia syndrome: an emerging but controversial condition. JAMA (1987) 257:2782-7. doi:10.1001/jama.1987.03390200122026
151. Wallace D, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (2001) 40:743-9. doi:10.1093/rheumatology/40.7.743
152. Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatology (Oxford) (2008) 47:1223-7. doi:10.1093/rheumatology/ken140
153. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J Rheumatol (1999) 26:1167-71
154. Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Rheumatology (1991) 30:220-2. doi:10.1093/rheumatology/30.3.220
155. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci (1991) 36:59-64. doi:10.1007/BF01300088
156. Sivri A, Cindas A, Dinçer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol (1996) 15:283-6. doi:10.1007/BF02229708
157. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol (1999) 94:3541-6. doi:10.1111/j.1572-0241.1999.01643.x
158. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis (2004) 63:450-2. doi:10.1136/ard.2003.011502
159. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol (2003) 56:481-90. doi:10.1136/jcp.56.7.481
160. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 34:501-37. doi:10.1016/j.semarthrit.2004.07.002
161. Hevia A, Milani C, López P, Cuervo A, Arboleya S, Duranti S, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. MBio (2014) 5:e1548-1514. doi:10.1128/mBio.01548-14
162. Rojo D, Hevia A, Bargiela R, López P, Cuervo A, González S, et al. Ranking the impact of human health disorders on gut metabolism: systemic lupus erythematosus and obesity as study cases. Sci Rep (2015) 5:8310-8310. doi:10.1038/srep08310
163. López P, de Paz B, Rodríguez-Carrio J, Hevia A, Sánchez B, Margolles A, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients. Sci Rep (2016) 6:24072-24072. doi:10.1038/srep24072
164. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 308:302-7. doi:10.1056/NEJM198302103080602
165. Vossen JM, Guiot HF, Lankester AC, Vossen AC, Bredius RG, Wolterbeek R, et al. Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation. PLoS One (2014) 9:e105706. doi:10.1371/journal.pone.0105706
166. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood (1999) 93:3267-75
167. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 209:903-11. doi:10.1084/jem.20112408
168. Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant (2014) 20:640-5. doi:10.1016/j.bbmt.2014.01.030
169. Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, et al. Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. Bone Marrow Transplant (2015) 50:992-8. doi:10.1038/bmt.2015.16
170. Simms-Waldrip T, Meir M, Fan D, Coughlin L, Savani M, Watt T, et al. The role of gut microbiota in the development of intestinal GVHD. Biol Blood Marrow Transplant (2014) 20:S55-6. doi:10.1016/j.bbmt.2013.12.060
171. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant (2015) 21:1373-83. doi:10.1016/j.bbmt.2015.04.016
172. Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M, et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood (2015) 126:1723-8. doi:10.1182/blood-2015-04-638858
173. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med (2016) 8:339ra71. doi:10.1126/scitranslmed.aaf2311
174. Weber D, Oefner PJ, Dettmer K, Hiergeist A, Koestler J, Gessner A, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 51:1087-92. doi:10.1038/bmt.2016.66
175. Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. Blood (2016) 128(16):2083-8. doi:10.1182/blood-2016-05-717652